Delivering on the promise of RNA therapeutics
Our in-house pipeline is focused on rare Genetic Skeletal Disorders which account for 5% of all birth defects and are an important cause of disability worldwide, yet very few have personalised treatments. In partnership, we are also developing the world’s 1st topical RNA interference therapy in rare ophthalmic disease.
Team
Founded and led by an authority in nanoparticle science for therapeutics, Dr Suzanne Saffie-Siebert Ph.D., our expert team and academic partners are focused on the translation of cutting-edge research into safe, effective, and accessible drugs for currently untreatable diseases.
Technology
Our proprietary BIO-COURIER technologies include a next-generation, non-viral, silicon stabilized hybrid Lipid Nanoparticle (sshLNP) to improve the stability, storage, delivery, and immunogenicity of RNA therapeutics.
Why Sisaf?
We are in the midst of a RNA therapeutic revolution, the likes of which have not been seen since the advent of recombinant protein technology almost 50 years ago. SiSaf is at the forefront of stabilizing, storing, and delivering RNA therapeutics, ultimately increasing their access to the global population.